Long-term care, care needs and wellbeing of individuals after cancer in childhood or adolescence (VersKiK): study protocol of a large scale multi-methods non-interventional study.

Cancer Cancer survivorship Follow-up guidelines Follow-up studies Informal caregivers Insurance claims processing Late effect Transition to adult care

Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
20 Sep 2022
Historique:
received: 14 07 2022
accepted: 08 09 2022
entrez: 20 9 2022
pubmed: 21 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

It has been shown previously that a relevant proportion of childhood cancer survivors suffers from late effects, which are often directly related to the cancer itself or its therapy, resulting in particular follow-up needs, additionally burdening healthcare systems. Being diagnosed with cancer at a vulnerable stage of development, this group of cancer survivors is at comparatively higher risk of relapse or subsequent cancer. Although national and international follow-up guidelines based on treatment modalities have been developed, their implementation seems to leave room for improvement. Additionally, they lack a sufficient consideration of the survivors' psychosocial needs, affecting their adherence to them. The aim of the VersKiK study is to provide representative information on late effects in childhood and adolescence cancer survivors in Germany. The main research objectives are: (1) to describe the state of follow-up care among survivors after a cancer diagnosis in childhood or adolescence; (2) to quantify the occurrence of late effects among this group of survivors; (3) to examine the adherence to selected audiological and cardiological follow-up guidelines and to identify factors affecting it; (4) to explore actual follow-up needs of paediatric cancer survivors; (5) to review selected follow-up guidelines with the aim to improve and expand them. VersKiK is designed as a mixed-methods non-interventional study. We will use claims data from statutory health insurance companies in combination with individually linked population-based registry data from the German Childhood Cancer Registry (GCCR). This data base will permit us to quantify diagnoses and procedures in comparison to the general population as well as the adherence to existing follow-up guidelines. Additional information will be obtained through interviews with childhood and adolescence cancer survivors and their informal caregivers, as well as in focus groups with healthcare professionals. The present study aims to research the actual needs of individuals after cancer diagnosis and treatment in childhood or adolescence - physical, psychological and organisational - in order to improve existing follow-up guidelines. These improvements might further positively affect not only actual care provided to paediatric cancer survivors, but also benefit healthcare systems in general while decreasing consequent medical visits in this group of patients. Registered at German Clinical Trial Register (ID: DRKS00025960 and DRKS00026092).

Sections du résumé

BACKGROUND BACKGROUND
It has been shown previously that a relevant proportion of childhood cancer survivors suffers from late effects, which are often directly related to the cancer itself or its therapy, resulting in particular follow-up needs, additionally burdening healthcare systems. Being diagnosed with cancer at a vulnerable stage of development, this group of cancer survivors is at comparatively higher risk of relapse or subsequent cancer. Although national and international follow-up guidelines based on treatment modalities have been developed, their implementation seems to leave room for improvement. Additionally, they lack a sufficient consideration of the survivors' psychosocial needs, affecting their adherence to them. The aim of the VersKiK study is to provide representative information on late effects in childhood and adolescence cancer survivors in Germany. The main research objectives are: (1) to describe the state of follow-up care among survivors after a cancer diagnosis in childhood or adolescence; (2) to quantify the occurrence of late effects among this group of survivors; (3) to examine the adherence to selected audiological and cardiological follow-up guidelines and to identify factors affecting it; (4) to explore actual follow-up needs of paediatric cancer survivors; (5) to review selected follow-up guidelines with the aim to improve and expand them.
METHODS METHODS
VersKiK is designed as a mixed-methods non-interventional study. We will use claims data from statutory health insurance companies in combination with individually linked population-based registry data from the German Childhood Cancer Registry (GCCR). This data base will permit us to quantify diagnoses and procedures in comparison to the general population as well as the adherence to existing follow-up guidelines. Additional information will be obtained through interviews with childhood and adolescence cancer survivors and their informal caregivers, as well as in focus groups with healthcare professionals.
DISCUSSION CONCLUSIONS
The present study aims to research the actual needs of individuals after cancer diagnosis and treatment in childhood or adolescence - physical, psychological and organisational - in order to improve existing follow-up guidelines. These improvements might further positively affect not only actual care provided to paediatric cancer survivors, but also benefit healthcare systems in general while decreasing consequent medical visits in this group of patients.
TRIAL REGISTRATION BACKGROUND
Registered at German Clinical Trial Register (ID: DRKS00025960 and DRKS00026092).

Identifiants

pubmed: 36127717
doi: 10.1186/s12913-022-08549-3
pii: 10.1186/s12913-022-08549-3
pmc: PMC9487026
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1176

Subventions

Organisme : Gemeinsame Bundesausschuss
ID : 01VSF19013

Informations de copyright

© 2022. The Author(s).

Références

J Cancer Surviv. 2019 Aug;13(4):620-631
pubmed: 31273639
J Cancer Surviv. 2019 Oct;13(5):759-772
pubmed: 31396878
Int J Nurs Stud. 2014 Jan;51(1):123-35
pubmed: 23490470
Oncol Res Treat. 2018;41(7-8):430-436
pubmed: 29902787
Oncol Res Treat. 2017;40(12):746-750
pubmed: 29183026
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Crit Rev Oncol Hematol. 2017 Dec;120:60-76
pubmed: 29198339
JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
J Cancer Surviv. 2017 Oct;11(5):614-623
pubmed: 28785871
Support Care Cancer. 2016 Sep;24(9):3967-77
pubmed: 27126772
PLoS Med. 2017 May 9;14(5):e1002296
pubmed: 28486495
Cancer. 2000 Apr 1;88(7):1687-95
pubmed: 10738228
Gesundheitswesen. 2015 Feb;77(2):120-6
pubmed: 25622207
J Cancer Surviv. 2016 Aug;10(4):611-8
pubmed: 26868681
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Eur J Oncol Nurs. 2009 Jul;13(3):207-12
pubmed: 19539526
BMJ Support Palliat Care. 2020 Sep 21;:
pubmed: 32958504
Pediatr Blood Cancer. 2020 Mar;67(3):e28090
pubmed: 31774240
J Pers Soc Psychol. 1996 Aug;71(2):230-44
pubmed: 8765481
Int J Cancer. 2015 Sep 1;137(5):1176-86
pubmed: 25648592
Ann Oncol. 2012 Aug;23(8):2191-2198
pubmed: 22312159
Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7
pubmed: 11345808
BMC Public Health. 2020 Aug 26;20(1):1290
pubmed: 32847501
Int J Nurs Stud. 2021 Mar;115:103851
pubmed: 33360499
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12649
pubmed: 28134478
JACC CardioOncol. 2020 Sep 15;2(3):363-378
pubmed: 34396245
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Patient Educ Couns. 2008 Mar;70(3):305-14
pubmed: 18155388
J Pediatr Psychol. 2001 Jun;26(4):225-35
pubmed: 11329482
Int J Environ Res Public Health. 2021 Aug 08;18(16):
pubmed: 34444141
J Cancer Surviv. 2018 Jun;12(3):277-290
pubmed: 29222704
Eur J Cancer. 2008 Jan;44(2):257-68
pubmed: 17981026
Heart. 2021 Jan;107(1):33-40
pubmed: 32826285
J Am Heart Assoc. 2019 Jan 8;8(1):e009122
pubmed: 30595059
Front Horm Res. 2021;54:16-24
pubmed: 34569544
BMC Cancer. 2017 Nov 6;17(1):715
pubmed: 29110686
Psychooncology. 2018 Jun;27(6):1501-1508
pubmed: 29473254
J Cancer Surviv. 2019 Oct;13(5):713-729
pubmed: 31338733
J Cancer Surviv. 2016 Jun;10(3):505-13
pubmed: 26572903
BMC Health Serv Res. 2021 May 25;21(1):503
pubmed: 34034742
Implement Sci. 2012 Apr 24;7:37
pubmed: 22530986
Oncol Res Treat. 2020;43(3):61-69
pubmed: 31931503
Support Care Cancer. 2021 Sep;29(9):4957-4968
pubmed: 33569673
Lancet Reg Health Eur. 2022 Jun;17:100398
pubmed: 35573974
Int J Cancer. 2022 Jan 1;150(1):67-72
pubmed: 34431525
Pediatr Blood Cancer. 2008 May;50(5):1018-25
pubmed: 17849473
JAMA. 2007 Jun 27;297(24):2705-15
pubmed: 17595271
PLoS One. 2022 May 26;17(5):e0267317
pubmed: 35617253
BMC Cancer. 2012 Apr 18;12:150
pubmed: 22510387

Auteurs

E Aleshchenko (E)

Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto Von Guericke Univiersity, Magdeburg, Germany. ekaterina.aleshchenko@med.ovgu.de.

E Swart (E)

Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto Von Guericke Univiersity, Magdeburg, Germany.

C Spix (C)

Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany.

M Voigt (M)

Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany.

P Trocchi (P)

Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto Von Guericke Univiersity, Magdeburg, Germany.

T Langer (T)

University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

G Calaminus (G)

Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.

K Baust (K)

Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.

J Glogner (J)

Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.

P Ihle (P)

PMV Research Group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University of Cologne, Köln, Germany.

J Küpper-Nybelen (J)

PMV Research Group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University of Cologne, Köln, Germany.

C Lüpkes (C)

OFFIS-Institute for Information Technology, Oldenburg, Germany.

T Kloppe (T)

OFFIS-Institute for Information Technology, Oldenburg, Germany.

D Horenkamp-Sonntag (D)

Techniker Krankenkasse (TK), Hamburg, Germany.

I Meier (I)

Techniker Krankenkasse (TK), Hamburg, Germany.

U Marschall (U)

BARMER, Wuppertal, Germany.

P Dröge (P)

AOK Research Institute (WIdO), Berlin, Germany.

M Klein (M)

DAK-Gesundheit, Hamburg, Germany.

A Weiss (A)

Medical Sociology, Institute for Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Bavarian Care and Nursing Authority, Amberg, Germany.

C Apfelbacher (C)

Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto Von Guericke Univiersity, Magdeburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH